Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’” - 14/04/23
Doi : 10.1016/j.jaad.2019.03.006
Luca Schneller-Pavelescu, MD a, ⁎ 
, Eduardo Vergara-de Caso, MD a, Antonio Martorell, MD b, Jorge Romaní, MD, PhD c, Mireya Lázaro, MD d, Eva Vilarrasa, MD e, Blanca Díaz-Ley, MD f, Igor Vázquez-Osorio, MD g, Juan Manuel Segura Palacios, MD h, José Manuel Azaña, MD i, Marcos Antonio González-López, MD j, Javier Cañueto, MD k, Alejandro Molina-Leyva, MD l, María Leiva-Salinas, MD m, Francisco José Navarro-Triviño, MD n, José Sánchez-Payá, MD o, José C. Pascual, MD a
, Eduardo Vergara-de Caso, MD a, Antonio Martorell, MD b, Jorge Romaní, MD, PhD c, Mireya Lázaro, MD d, Eva Vilarrasa, MD e, Blanca Díaz-Ley, MD f, Igor Vázquez-Osorio, MD g, Juan Manuel Segura Palacios, MD h, José Manuel Azaña, MD i, Marcos Antonio González-López, MD j, Javier Cañueto, MD k, Alejandro Molina-Leyva, MD l, María Leiva-Salinas, MD m, Francisco José Navarro-Triviño, MD n, José Sánchez-Payá, MD o, José C. Pascual, MD a a Department of Dermatology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-FISABIO Foundation), Alicante, Spain
b Department of Dermatology, Hospital de Manises, Valencia, Spain
c Department of Dermatology, Corporació Sanitaria Parc Taulí, Sabadell, Spain
d Department of Dermatology, Hospital de Basurto, Bilbao (Vizcaya), Spain
e Department of Dermatology, Hospital de la Santa Creui Sant Pau, Barcelona, Spain
f Department of Dermatology, Hospital del Sureste, Arganda del Rey, Spain
g Department of Dermatology, Hospital de Cabueñes, Gijón, Spain
h Department of Dermatology, Hospital Costa del Sol, Marbella, Spain
i Department of Dermatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain
j Department of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
k Department of Dermatology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
l Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain
m Department of Dermatology, Hospital Marina Baixa, Villajoyosa, Spain
n Department of Dermatology, Hospital Comarcal Santa Ana, Motril, Spain
o Epidemiology Unit, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-FISABIO Foundation), Alicante, Spain
∗Reprint requests: Luca Schneller-Pavelescu, MD, Department of Dermatology, Alicante University General Hospital, Pintor Baeza 11 St, Alicante, 03010, SpainDepartment of DermatologyAlicante University General HospitalPintor Baeza 11 StAlicante03010Spain
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Pascual has been an advisory board member for Abbvie. Dr Romaní has given lectures or been an advisory board member for Abbvie, Almirall, Novartis, and Leopharma. Dr Vilarrasa has received consultancy/speakers' honoraria and/or participated in clinical trials sponsored by AbbVie, Almirall, Boheringer, Celgene, Janssen, Leo Pharma, Eli Lilly and Company, MSD, Novartis, and Pfizer. Dr Azaña has received consultancy/speakers honoraria from AbbVie. Dr González-López has given lectures for Abbvie. Dr Cañueto has given lectures for AbbVie. Dr Schneller-Pavelescu, Dr Vergara-de Caso, Dr Martorell, Dr Lázaro, Dr Díaz-Ley, Dr Vázquez-Osorio, Dr Segura Palacios, Dr Molina-Leyva, Dr Leiva-Salinas, Dr Navarro-Triviño, MD, and Dr Sánchez-Payá have no conflicts of interest to declare. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 88 - N° 5
P. e271-e272 - mai 2023 Retour au numéro
Article précédent
- Comment on “Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes”
- Claudio Marasca, Anna Masarà, Maria Carmela Annunziata, Davide Fattore, Gabriella Fabbrocini
- Dissolution at acidic pH, not dermatoscopy, is the preferred method to test the quality of itraconazole pellets
- Deepak Jakhar, Ishmeet Kaur, Raj Kumar Mehta
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?